Lexicon Pharmaceuticals, Inc. Profile

Industry

Biotechnology

Sector

Healthcare

Number of Employees

285

Lexicon Pharmaceuticals's Business Model

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.

About Lexicon Pharmaceuticals

Website: https://www.lexpharma.com

CEO (Chief Executive Officer): Mr. Lonnel Coats

IPO date: 2000-04-07

Contact

Country: US

Address: 2445 Technology Forest Boulevard

City: The Woodlands

State: TX

Phone: 281 863 3000

Zip Code: 77381

Other

CIK: 0001062822

ISIN: US5288723027

CUSIP: 528872302

Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.